Funding for this research was provided by:
Bristol-Myers Squibb Company (N/A)
Received: 30 April 2020
Accepted: 19 August 2020
First Online: 10 September 2020
Ethics approval and consent to participate
: This study was conducted in accordance with the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Epidemiology Practices and the ethical principles that have their origin in the Declaration of Helsinki. The laws and regulatory requirements in Portugal were followed. The protocol received approval by the Institutional Review Board (IRB; Ethics Committee of the Portuguese Oncology Institute of Porto). This was a retrospective observational study using anonymised patient data. Patients were not contacted or directly impacted by study participation in any way, thus obtaining informed consent was not applicable.
: Not applicable.
: MS, LA, PR, MB, and MJB are employees of IPO-Porto.MB received personal fees and non-financial support from Roche and non-financial support from Janssen outside the submitted work.FRG has no competing interests.RH, DP, FG, and RM are employees of IQVIA.CC, MD, JRP, and JCO are employees of Bristol Myers Squibb.CC and JRP report stock ownership in Bristol Myers Squibb.LL was contracted (paid) as consultant by Bristol Myers Squibb to support the I-O Optimise initiative and is an employee of Epi-Fit.